CABA - Cabaletta Bio, Inc.
IEX Last Trade
2.32
-0.025 -1.078%
Share volume: 3,155
Last Updated: Thu 26 Dec 2024 04:30:27 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$2.34
-0.03
-1.07%
Fundamental analysis
14%
Profitability
4%
Dept financing
11%
Liquidity
50%
Performance
15%
Performance
5 Days
-1.68%
1 Month
2.18%
3 Months
-40.76%
6 Months
-67.59%
1 Year
-89.43%
2 Year
-72.41%
Key data
Stock price
$2.32
DAY RANGE
$2.24 - $2.37
52 WEEK RANGE
$2.01 - $26.35
52 WEEK CHANGE
-$89.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Steven Nichtberger
Region: US
Website: www.cabalettabio.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: www.cabalettabio.com
Employees: 50
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
Recent news